Ordering Recommendation

Screening test for Lynch Syndrome. Determine potential eligibility for immunotherapy by identifying microsatellite instability-high (MSI-H) cancers. 


Polymerase Chain Reaction/Fragment Analysis


DNA isolation: Sun-Sat
Assay: Sun, Tue, Thu


10-20 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation

Tumor AND normal epithelial tissue. Also acceptable: DNA extracted by CLIA certified

Specimen Preparation

Tissue: Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect from excessive heat. Tissue block will be returned after testing. Transport tissue block(s) or 10 unstained 5-micron slides (5 tumor and 5 normal epithelial). (Min: 3 tumor tissue and 3 normal epithelial tissue slides) Transport block(s) and/or slide(s) in a tissue transport kit (ARUP Supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787.
Extracted DNA: Transport 40 uL DNA with at least 50 ng/uL concentration. (Min: 40 uL)Transport DNA in a tissue transport kit (ARUP Supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787.

Storage/Transport Temperature

Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months
Extracted DNA: Refrigerated.

Unacceptable Conditions

Less than 25 percent tumor or less than 50 percent normal epithelial tissue. DNA extracted by a non-CLIA lab. DNA extracted without a corresponding circled H&E slide. Specimens fixed/processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5). Decalcified specimens.


Include surgical pathology report.


Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Extracted DNA: Ambient: 1 month; Refrigerated: Indefinitely; Frozen: Indefinitely

Reference Interval
Interpretive Data

Refer to report.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Hotline History
CPT Codes

88381; 81301

Component Test Code* Component Chart Name LOINC
0051741 Microsatellite Marker BAT-25
0051742 Microsatellite Marker BAT-26
0051743 Microsatellite Marker MONO-27
0051744 Microsatellite Interpretation 43368-0
0051745 Microsatellite Marker NR-21
0051746 Microsatellite Marker NR-24
2001370 Microsatellite Instability Specimen 31208-2
2002148 Block ID 57723-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • BAT -25, BAT-26, MON-27, NR-21, NR-24 genotypes
  • HNPCC tumor screening
  • Lynch Syndrome MSI
  • Lynch syndrome tumor screening
  • microsatellite instability
  • MSI
  • MSI Lynch syndrome
Microsatellite Instability (MSI), HNPCC/Lynch Syndrome, by PCR